Abstract:Glioblastoma, the most common aggressive cancer, has a poor prognosis. Among the current standard treatment strategies, radiation therapy is the most commonly recommended. However, it is often unsuccessful at completely eliminating the cancer from the brain. A combination of radiation with other treatment methods should therefore be considered. It has been reported that radiotherapy in combination with immunotherapy might show a synergistic effect; however, this still needs to be investigated. In the current study, a "branched multipeptide and peptide adjuvants [such as pan DR epitope (PADRE) and polyinosinic-polycytidylic acid—stabilized with polylysine and carboxymethylcellulose—(poly-ICLC)]," namely vaccine and anti-PD1, were used as components of immunotherapy to assist in the anti-tumor effects of radiotherapy against glioblastomas. With regard to experimental design, immunological characterization of GL261 cells was performed and the effects of radiation on this cell line were also evaluated. An intracranial GL261 mouse glioma model was established, and therapeutic effects were observed based on tumor size and survival time. The distribution of effector immune cells in the spleen, based on cytotoxic T lymphocyte (CTL) and natural killer (NK) cell function, was determined. The pro-inflammatory and anti-inflammatory cytokine production from re-stimulated splenocytes and single tumor cells were also evaluated. As GL261 cells demonstrated both immunological characteristics and radiation sensitivity, they were found to be promising candidates for testing this combination treatment. Combinatorial treatment with radiation, vaccine, and anti-PD1 prolonged mouse survival by delaying tumor growth. Although this combination treatment led to an increase in the functional activity of both CTLs and NK cells, as evidenced by the increased percentage of these cells in the spleen, there was a greater shift toward CTL rather than NK cell activity. Moreover, the released cytokines from re-stimulated splenocytes and single tumor cells also showed a shift toward the pro-inflammatory response. This study suggests that immunotherapy comprising a branched multipeptide plus PADRE, poly-ICLC, and anti-PD1 could potentially enhance the anti-tumor effects of radiotherapy in a glioblastoma mouse model.

Improved Therapeutic Efficacy Using Vaccination with Glioma Lysate-Pulsed Dendritic Cells Combined with IP-10 in Murine Glioma

Dendritic cells pulsed with glioma RNA induce immunity against intracranial gliomas

Immunotherapy of Intracranial G422 Glioblastoma with Dendritic Cells Pulsed with Tumor Extract or RNA

Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model

Experimental Study of Treatment ofIntracranial G422 Glioblastoma with Bone Marrow-derived Dendritic Cells Vaccine

Treatment of Intracranial G422 Glioblastoma with Bone Marrow-Derived Dendritic Cells Pulsed with Tumor Extracts

Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells

An Experimental Study of Dendritic Cell-Based Vaccine Therapy for Intracranial Gliomas

Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma

Specific T Cell Immunotherapy Against Glioblastoma with Mouse Model

Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model

The Enhanced Anti-Angiogenic and Antitumor Effects of Combining Flk1-Based Dna Vaccine and Ip-10

An Experimental Study of Vaccines for Treatment in Intracranial Gliomas by Dendritic Cells Pulsed with Apoptotic Tumor Cells

Targeted in Vivo Expression of IFN-gamma-inducible Protein 10 Induces Specific Antitumor Activity.

Co-delivery of Tumor-Derived Exosomes with Alpha-Galactosylceramide on Dendritic Cell-Based Immunotherapy for Glioblastoma

Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors

Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

Targeted in vivo expression of IFN-γ-inducible protein 10 induces specific antitumor activity

IP10 enhances anti-tumor immunity and its mechanisms

Recruiting T Cells towards Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co‐delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage Membrane‐Camouflaged Nano Vesicles

Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model